Lukáš Urban

Lukáš Urban

Auto-generated profile, based on publicly available information

Lukáš Urban

Department of Pharmacology, Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovakia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MČMatúš Čoma
Matúš Čoma
LFLucia Fröhlichová
Lucia Fröhlichová
LULukáš Urban
Lukáš Urban
RZRobert Zajíček
Robert Zajíček
TUTomáš Urban
Tomáš Urban
Peter GalPeter Gal
Peter Gal
Excessive connective tissue accumulation, a hallmark of hypertrophic scaring, results in progressive deterioration of the structure and function of organs. It can also be seen during tumor growth and other fibroproliferative disorders. These processes result from a wide spectrum of cross-talks between mesenchymal, epithelial and inflammatory/immune cells that have not yet been fully understood. In the present review, we aimed to describe the molecular features of fibroblasts and their interactions with immune and epithelial cells and extracellular matrix. We also compared different types of fibroblasts and their roles in skin repair and regeneration following burn injury. In summary, here we briefly review molecular changes underlying hypertrophic scarring following burns throughout all basic wound healing stages, i.e. during inflammation, proliferation and maturation.

14 September 2023 in Histochemistry and Cell Biology
Verified
Journal Article
Open access
PDF file
LULukáš Urban
Lukáš Urban
MČMatúš Čoma
Matúš Čoma
Lukas LacinaLukas Lacina
Lukas Lacina
PSPavol Szabo
Pavol Szabo
JSJana Sabová
Jana Sabová
Peter GalPeter Gal
Peter Gal
Identification of therapeutic targets for treating fibrotic diseases and cancer remains challenging. Our study aimed to investigate the effects of TGF-β1 and TGF-β3 on myofibroblast differentiation and extracellular matrix deposition in different types of fibroblasts, including normal/dermal, cancer-associated, and scar-derived fibroblasts. When comparing the phenotype and signaling pathways activation we observed extreme heterogeneity of studied markers across different fibroblast populations, even within those isolated from the same tissue. Specifically, the presence of myofibroblast and deposition of extracellular matrix were dependent on the origin of the fibroblasts and the type of treatment they received (TGF-β1 vs. TGF-β3). In parallel, we detected activation of canonical signaling (pSMAD2/3) across all studied fibroblasts, albeit to various extents. Treatment with TGF-β1 and TGF-β3 resulted in the activation of canonical and several non-canonical pathways, including AKT, ERK, and ROCK. Among studied cells, cancer-associated fibroblasts displayed the most heterogenic response to TGF-β1/3 treatments. In general, TGF-β1 demonstrated a more potent activation of signaling pathways compared to TGF-β3, whereas TGF-β3 exhibited rather an inhibitory effect in keloid- and hypertrophic scar-derived fibroblasts suggesting its clinical potential for scar treatment. In summary, our study has implications for comprehending the role of TGF-β signaling in fibroblast biology, fibrotic diseases, and cancer. Future research should focus on unraveling the mechanisms beyond differential fibroblast responses to TGF-β isomers considering inherent fibroblast heterogeneity.

22 April 2020 in Molecules
Verified
Journal Article
Open access
PDF file
IKIvan Kováč
Ivan Kováč
NMNikola Melegová
Nikola Melegová
MČMatúš Čoma
Matúš Čoma
PTPeter Takac
Peter Takac
KKKatarína Kováčová
Katarína Kováčová
Peter GalPeter Gal
Peter Gal
The ability of horse chestnut extract (HCE) to induce contraction force in fibroblasts, a process with remarkable significance in skin repair, motivated us to evaluate its wound healing potential in a series of experiments. In the in vitro study of the ability of human dermal fibroblasts to form myofibroblast-like cells was evaluated at the protein level (Western blot and immunofluorescence). The in vivo study was conducted on male Sprague-Dawley rats with inflicted wounds (one open circular and one sutured incision) on their backs. Rats were topically treated with two tested HCE concentrations (0.1% and 1%) or sterile water. The control group remained untreated. The incisions were processed for wound tensile strength (TS) measurement whereas the open wounds were subjected to histological examination. On the in vitro level the HCE extract induced fibronectin-rich extracellular matrix formation, but did not induced α-smooth muscle actin (SMA) expression in dermal fibroblasts. The animal study revealed that HCE increased wound TS and improved collagen organization. In conclusion, the direct comparison of both basic wound models demonstrated that the healing was significantly increased following HCE, thus this extract may be found useful to improve healing of acute wounds. Nevertheless, the use of an experimental rat model warrants a direct extrapolation to the human clinical situation.

21 November 2024 in Veterinary Research Communications
Verified
Journal Article
Open access
PDF file
ZTZuzana Tirpáková
Zuzana Tirpáková
ZDZuzana Demcisakova
Zuzana Demcisakova
LLLenka Luptakova
Lenka Luptakova
JHJulia Hurnikova
Julia Hurnikova
MČMatúš Čoma
Matúš Čoma
EPEva Petrovova
Eva Petrovova
In recent years, the chorioallantoic membrane (CAM) has emerged as a crucial component of biocompatibility testing for biomaterials designed for regenerative strategies and tissue engineering applications. This study explores angiogenic potential of an innovative acellular and porous biopolymer scaffold, based on polyhydroxybutyrate and chitosan (PHB/CHIT), using the ex ovo quail CAM assay as an alternative to the conventional chick CAM test. On embryonic day 6 (ED6), we placed the tested biomaterials on the CAM alone or soaked them with various substances, including vascular endothelial growth factor (VEGF-A), saline, or the endogenous angiogenesis inhibitor Angiostatin. After 72 h (ED9), we analyzed blood vessels formation, a sign of ongoing angiogenesis, in the vicinity of the scaffold and within its pores. We employed marker for cell proliferation (PHH3), embryonic endothelium (WGA, SNA), myofibroblasts (α-SMA), and endothelial cells (QH1) for morphological and histochemical analysis. Our findings demonstrated the robust angiogenic potential of the untreated scaffold without additional influence from the angiogenic factor VEGF-A. Furthermore, gene expression analysis revealed an upregulation of pro-angiogenic growth factors, including VEGF-A, ANG-2, and VE-Cadherin after 5 days of implantation, indicative of a pro-angiogenic microenvironment. These results underscore the inherent angiogenic potential of the PHB/CHIT composite. Additionally, monitoring of CAM microvilli growing to the scaffold provides a methodology for investigating the biocompatibility of materials using the ex ovo quail CAM assay as a suitable alternative model compared to the chicken CAM platform. This approach offers a rapid screening method for biomaterials in the field of tissue repair/regeneration and engineering.

10 March 2026 in Bratislava Medical Journal
Verified
Journal Article
Open access
PDF file
JSJana Sabová
Jana Sabová
AFAnnamária Ferčáková
Annamária Ferčáková
LULukáš Urban
Lukáš Urban
VRVeronika Roškovičová
Veronika Roškovičová
JKJana Katuchova
Jana Katuchova
Peter GalPeter Gal
Peter Gal
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense desmoplastic stroma that contributes to tumor progression, therapeutic resistance, and disease aggressiveness. Cancer-associated fibroblasts (CAFs) represent the predominant cellular component of this stroma and are a major source of extracellular matrix (ECM), playing a central role in shaping the tumor microenvironment. However, the reliable isolation of CAFs from human PDAC tissue remains technically challenging due to extensive matrix deposition, limited tissue availability, and an elevated risk of microbial contamination. In this study, we comparatively evaluated two isolation workflows using freshly resected human PDAC specimens: (i) mechanical explant-based outgrowth and (ii) combined mechanical-enzymatic dissociation with trypsin pre-digestion. In parallel, we evaluated graded antibiotic and antimycotic regimens to optimize contamination control during the initial culture period. The addition of amphotericin B to the culture medium effectively reduced contamination risk without compromising fibroblast outgrowth when withdrawn in a stepwise manner. Furthermore, gentle enzymatic pre-digestion enhanced overall isolation efficiency without affecting the timing of initial fibroblast outgrowth. Phenotypic characterization confirmed fibroblast identity and demonstrated comparable expression of activation-associated markers, although inter-sample variability was observed in signaling receptor expression, including PDGFR- α and PDGFR- β . Collectively, these findings establish a practical and reproducible protocol for isolating primary PDAC-derived CAFs suitable for downstream experimental studies of the tumor microenvironment.

4 June 2026 in Bratislava Medical Journal
Verified
Journal Article
Open access
JSJana Sabová
Jana Sabová
LVLenka Varinská
Lenka Varinská
LULukáš Urban
Lukáš Urban
Peter GalPeter Gal
Peter Gal
MČMatúš Čoma
Matúš Čoma
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies and remains highly resistant to systemic chemotherapy. Tigecycline, a glycylcycline antibiotic that inhibits mitochondrial translation, has recently attracted attention as a potential candidate for drug repurposing in oncology because of its proposed chemosensitizing effects. The aim of this study was to evaluate the cytotoxic and chemosensitizing effects of tigecycline in combination with clinically relevant PDAC chemotherapy regimens, namely FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin) and Gem-Pac (gemcitabine plus nab-paclitaxel). The individual components of these regimens were applied at clinically relevant molar ratios reflecting patient treatment protocols. Experiments were performed using both 2D monolayer cultures and 3D spheroid models of four PDAC cell lines (PaTu-8902, PANC-1, MIAPaCa-2, and Capan-2). Cell viability and proliferation were assessed using MTS assay, BrdU incorporation, and CellTiter-Glo ® 3D assays, and spheroid growth dynamics were quantified by imaging-based area measurements after 3 days of treatment. Tigecycline enhanced the cytotoxic effects of both chemotherapy regimens in a concentration- and cell line-dependent manner, with a more pronounced effect observed in combination with Gem-Pac. In MTS assays, tigecycline converted otherwise chemoresistant cell lines (PaTu-8902, PANC-1, and MIAPaCa-2) into more responsive phenotypes, with the strongest sensitization observed in PaTu-8902 cells. Δ effect analysis further revealed that tigecycline-mediated sensitization to Gem-Pac occurred across a broad concentration range. Notably, this effect was evident even at lower, otherwise ineffective doses in Capan-2 cells. In contrast, the effect of tigecycline in combination with FOLFIRINOX was rather moderate and predominantly observed at higher concentrations. These trends were consistent with BrdU and 3D spheroid models, which supported the observed cell line-dependent differences in treatment response. Clinically relevant, tigecycline alone exhibited concentration-dependent cytotoxicity, with minimal effects at lower concentrations and more pronounced reductions in viability at higher doses. Overall, these findings demonstrate that tigecycline can enhance the efficacy of clinically relevant PDAC chemotherapy regimens in vitro and support its further preclinical evaluation as a potential adjunct to existing PDAC treatment strategies.